Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Synergy Asset Management LLC

Synergy Asset Management LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 44.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 106,500 shares of the biopharmaceutical company's stock after selling 85,305 shares during the period. Gilead Sciences makes up 1.5% of Synergy Asset Management LLC's investment portfolio, making the stock its 19th largest position. Synergy Asset Management LLC's holdings in Gilead Sciences were worth $11,933,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC lifted its position in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares during the last quarter. Whipplewood Advisors LLC acquired a new position in Gilead Sciences in the fourth quarter valued at about $35,000. Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $40,000. Lee Danner & Bass Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $41,000. Finally, Investment Research & Advisory Group Inc. lifted its holdings in shares of Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $108.50 on Friday. The firm has a market capitalization of $134.97 billion, a PE ratio of 22.84, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29. Gilead Sciences, Inc. has a fifty-two week low of $66.01 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The stock's 50-day simple moving average is $106.16 and its 200-day simple moving average is $102.81.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The company had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter last year, the company earned ($1.32) earnings per share. The firm's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.91%. Gilead Sciences's dividend payout ratio is currently 66.53%.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research reports. Wells Fargo & Company upped their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Finally, Oppenheimer reduced their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the transaction, the insider now owns 120,168 shares of the company's stock, valued at $13,238,908.56. The trade was a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the transaction, the chief financial officer now directly owns 165,110 shares in the company, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 48,500 shares of company stock worth $5,236,245. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.